A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells by Marverti, Gaetano et al.
 International Journal of 
Molecular Sciences
Article
A Peptidic Thymidylate-Synthase Inhibitor Loaded
on Pegylated Liposomes Enhances the Antitumour
Effect of Chemotherapy Drugs in Human Ovarian
Cancer Cells
Gaetano Marverti 1,* , Gaia Gozzi 1, Eleonora Maretti 2 , Angela Lauriola 1,†, Leda Severi 2,
Francesca Sacchetti 2, Lorena Losi 2, Salvatore Pacifico 3, Stefania Ferrari 2, Glauco Ponterini 2 ,
Eliana Leo 2, Maria Paola Costi 2,* and Domenico D’Arca 1,*
1 Department of Biomedical, Metabolic and Neural Sciences, Via G. Campi 287, University of Modena and
Reggio Emilia, 41125 Modena, Italy; g.gozzi@holostem.com (G.G.); angela.lauriola@univr.it (A.L.)
2 Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena,
Italy; eleonora.maretti@unimore.it (E.M.); leda.severi@gmail.com (L.S.); francesca.sacchetti@alice.it (F.S.);
lorena.losi@unimore.it (L.L.); sferrari591@gmail.com (S.F.); glauco.ponterini@unimore.it (G.P.);
elianagrazia.leo@unimore.it (E.L.)
3 Department of Chemical and Pharmaceutical Sciences, via Fossato di Mortara 17–19, University of Ferrara,
44100 Ferrara, Italy; salvatore.pacifico@unife.it
* Correspondence: gaetano.marverti@unimore.it (G.M.); mariapaola.costi@unimore.it (M.P.C.);
domenico.darca@unimore.it (D.D.)
† Present address: Department of Biotechnology, University of Verona, 37134 Verona, Italy.
Received: 30 May 2020; Accepted: 20 June 2020; Published: 23 June 2020


Abstract: There is currently no effective long-term treatment for ovarian cancer (OC) resistant
to poly-chemotherapy regimens based on platinum drugs. Preclinical and clinical studies have
demonstrated a strong association between development of Pt-drug resistance and increased
thymidylate synthase (hTS) expression, and the consequent cross-resistance to the hTS inhibitors
5-fluorouracil (5-FU) and raltitrexed (RTX). In the present work, we propose a new tool to combat drug
resistance. We propose to treat OC cell lines, both Pt-sensitive and -resistant, with dual combinations
of one of the four chemotherapeutic agents that are widely used in the clinic, and the new peptide,
hTS inhibitor, [D-Gln4]LR. This binds hTS allosterically and, unlike classical inhibitors that bind at
the catalytic pocket, causes cell growth inhibition without inducing hTS overexpression. The dual
drug combinations showed schedule-dependent synergistic antiproliferative and apoptotic effects.
We observed that the simultaneous treatment or 24h pre-treatment of OC cells with the peptide
followed by either agent produced synergistic effects even in resistant cells. Similar synergistic
or antagonistic effects were obtained by delivering the peptide into OC cells either by means of
a commercial delivery system (SAINT-PhD) or by pH sensitive PEGylated liposomes. Relative
to non-PEGylated liposomes, the latter had been previously characterized and found to allow
macrophage escape, thus increasing their chance to reach the tumour tissue. The transition from
the SAINT-PhD delivery system to the engineered liposomes represents an advancement towards a
more drug-like delivery system and a further step towards the use of peptides for in vivo studies.
Overall, the results suggest that the association of standard drugs, such as cDDP and/or 5-FU and/or
RTX, with the novel peptidic TS inhibitor encapsulated into PEGylated pH-sensitive liposomes can
represent a promising strategy for fighting resistance to cDDP and anti-hTS drugs.
Keywords: human thymidylate synthase peptidic-inhibitors; pH-sensitive PEGylated liposomes;
ovarian cancer; drug-resistance; raltitrexed; 5-fluorouracil
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1. Introduction
Ovarian cancer is the fifth cause of mortality among women of all ages in the Western
world. Although higher response rates have been achieved using the poly-chemotherapy regimens,
mainly based on the combination of cyclophosphamide or paclitaxel and a platinum compound, such as
cisplatin (cDDP) or carboplatin [1], many patients still die during cancer relapse and progression due
to the intrinsic or acquired resistance to chemotherapy as well as the genetic flexibility of the cancer
cell’s genome, resulting in multiple and often compensatory survival and proliferative signals, limiting
the activity of anti-cancer strategies and compelling the continuous search for new drug combinations.
Cisplatin is an alkylating agent that interacts with the DNA double strain structure and causes
formation of adducts that prevent transcription and cellular replication and induces apoptotic cell death.
In the multifactorial process of the acquired resistance to cDDP and its derivatives, the phenotypes
show overexpression of DNA-repair enzymes and enzymes necessary for the synthesis of thymidine,
such as thymidylate synthase (TS) and dihydrofolate reductase (DHFR), since they cause a rapid
turnover of DNA [2]. As a consequence, cells resistant to cDDP are also cross-resistant to the traditional
antifolates such as 5-fluorouracil (5-FU) and methotrexate (MTX) [3].
It is well known that tumours express higher TS levels than normal tissues and that the ovarian
tissue is among those with the highest levels of TS expression, a feature that correlates with poorer
patients’ overall survival [4]. 5-Fluorouracil and other antifolates, such as raltitrexed (RTX), inhibit
TS, but they may cause TS upregulation in cDDP-resistant cells. The active metabolite of 5-FU,
5-fluorodeoxyuridine monophosphate (5-FdUMP), inhibits the dTMP synthesis by forming a stable
ternary complex with TS and the methyl donor 5,10-methylene tetrahydrofolate (5,10-CH2THF) [5,6].
On the other hand, RTX is a TS cofactor analogue that inhibits TS with response rates similar to those
of 5-FU and, differently from the pyrimidine analogues, is not incorporated into DNA. It has been
licensed in many countries for the treatment of metastatic colorectal cancer [7,8]. Preclinical and clinical
studies have demonstrated a strong association between development of resistance to both 5-FU and
RTX and increased TS expression [9–11].
Exposure of cancer cells to 5-FU or other antifolate TS inhibitors acutely upregulates TS, probably
due to the inhibition of a negative-feedback mechanism in which the TS protein binds its own mRNA
and inhibits its translation [7,12,13]. In addition, TS behaves as an oncogene [14] by interfering with the
expression of proteins involved in the regulation of proliferative and survival pathways such as c-myc
and p53 by binding their mRNAs [15,16]. However, expression of wild-type p53 has been shown to be
required for 5-FU- and RTX-induced antitumor effects [17,18]. Therefore, new strategies helpful to
overcoming these TS-focused molecular mechanisms of chemo-resistance are required.
As one such strategy to obtain tumour cell death without inducing TS overexpression, we designed
oligopeptides able to modulate the equilibrium between the active TS conformation and the inactive
one. The novel mechanism of action involves binding at the monomer-monomer interface of the
enzyme, rather than at the catalytic pocket, with stabilization of the inactive conformation and decrease
of the abundance of the active form of the protein. Among these, the LR (LSCQLYQR) peptide
inhibited the growth of ovarian carcinomas (OCs) following transfection by means of a commercial
peptide delivery system, SAINT-PhD, while it left the TS cellular levels essentially unchanged [19,20].
More recently, among the peptides developed by modifying the LR lead to improve TS inhibition and
the anticancer effect, the D-glutamine-modified peptide at position 4 ([D-Gln4]LR) displayed the best
growth inhibition of both cDDP-sensitive and -resistant OC cell lines [21]; it was more active than LR
and 5-FU and affected the TS/DHFR expression pattern similarly to LR.
Proteomic studies have shown that, in human OC cell lines, these peptides modulate the
expression of a panel of six proteins, including TS and other important folate-related enzymes
such as phosphoribosylglycinamide formyltransferase (GART) and serine hydroxymethyltransferase
(SHMT1) [22]. The modulation of these proteins was markedly different from that induced by
pemetrexed (PMX), another TS inhibitor and a 5,10-CH2THF analogue, which, again, unlike the
peptide, binds at the TS active site.
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The possibility of combining conventional cytotoxic drugs with new agents that specifically
interfere with key pathways controlling cancer cell survival and proliferation is considered an
interesting and promising therapeutic approach. Indeed, if the cellular targets for these new agents
and/or their mechanism of action are different from those of conventional cytotoxic drugs, and if the
effects of the drugs combined on key pathways are concordant, their combination may act on the
sensitivity of cancer cells synergistically.
Recently, the hydrophilic peptide LR has been delivered into OC cells by exploiting such
biocompatible and efficient tools as solid lipid nanoparticles (SLNs) [23] and pH sensitive liposomes [24].
The ability to inhibit the cDDP-resistant OC cell growth demonstrated the efficacy of these nanosystems
in the internalization of the peptide into cells while preserving its activity. Enhanced effects are
expected when employing PEGylated liposomes. In fact, PEGylation represents a very useful method
for achieving long circulation time for liposomes, hence allowing them more time for targeting
tumours via the enhanced permeability and retention (EPR) effect [25]. The PEGylated pH-sensitive
liposomes were characterized and compared favourably with non-PEGylated ones regarding surface
hydrophilicity, stability in serum, interaction with macrophages, drug encapsulation efficiency and
drug release [26]. Also, the well-characterized intracellular mechanism of action of the [D-Gln4]LR
peptide delivered using the SAINT-PhD delivery system was unaltered when the latter was replaced
by these liposomes. While the commercial delivery system proved useful in the early cellular studies,
the PEGylated liposomes strategy is deemed necessary to implement further in vivo studies of the
[D-Gln4]LR peptide.
In the present study, we test the efficacy of combinations of RTX, cDDP and 5-FU with the
([D-Gln4]LR octapeptide, delivered into OC cells by either the SAINT-PhD delivery system or by
PEGylated pH-sensitive liposomes. More specifically, we investigate their cytotoxicities and abilities
to perturbate the cell cycle phase distribution. The microtubule polymer stabilizer paclitaxel was
also included in the described combination list, because the drug is largely used in ovarian cancer
chemotherapy and shows a different mechanism of action. To this aim, three different tumour-cell
treatment schedules were tested. Special attention was focused on the synergistic effects exhibited by
the combined cell treatments and the role of sequentially thereon.
2. Results
2.1. Sequence-Dependent Synergistic Antiproliferative Effects of [DGln4]LR/Drug Combinations
In cancer cells treated with 5-FU or RTX, alterations in TS expression were associated with
drug resistance response [7,12–14]. Despite the fact that these compounds and peptides share the
same target (TS), they have different molecular mechanisms of action and, thus, are not a priori
reciprocally competitive. Therefore, we investigated the potential cooperative antitumor effect of the
[DGln4]LR peptide in combination with these drugs, as well as with cDDP and paclitaxel, two other
chemotherapeutic agents used for the treatment of OC patients. We used cDDP-sensitive A2780 and
2008 cell lines and their cDDP-resistant counterparts, A2780/CP and C13*, to evaluate the combined
effect on cell proliferation of [DGln4]LR with either 5-FU, RTX, cDDP or paclitaxel by the synergism
Quotient (SQ) analysis. Among the different cell lines examined the IC50 values for the drugs alone
varied depending on the resistance phenotype (Table S1).
The [D-Gln4]LR peptide was delivered by the SAINT-PhD system to A2780 and A2780/CP cells
either concurrently or sequentially with the four drugs, each administered at concentrations lower
than the IC50 value (IC30) obtained with the drug alone on the tested cell line. As shown in the
diagrams in Figure 1, and synthesized by the heat map in Figure 4, most of the results of the concurrent
administration (sequence I) demonstrate additive or moderately supra-additive effects, as indicated by
SQ values around or slightly higher than 1, even in the cDDP-resistant A2780/CP cell line. On the other
hand, administration of the peptide followed by the drug (sequence II) caused an overall increase in
cell killing. This was evident with both cell lines in the treatment with the lower doses of all four drugs,
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while, at the higher doses, only 5-FU showed an improved performance with sequence II over the
concurrent administration.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 22 
 
 
Figure 1. Effects of scheduled combinations of the [D-Gln4]LR peptide with cDDP, pa+clitaxel, 5FU 
and RTX on the SQ values in A2780 and A2780/CP cell lines. (A) concurrent combinations for 72 h. 
(B) Sequential combinations, as described in Section 4. The bars represent the mean of duplicate cell 
counts on three separate experiments and indicate the result of the inhibition of drug combination 
divided by the sum of the inhibition of a single drug to obtain the values of SQ. Error bars, SD. 
With the second pair of cell lines, 2008 and C13*, concurrent administration was additive for 
cDDP, 5-FU, and paclitaxel at the lower dose, supra-additive at the higher dose of paclitaxel and for 
RTX at both doses (Figures 2 and 4). Sequential exposure to [D-Gln4]LR and then to the drugs did not 
enhance cell killing with the cDDP-sensitive 2008 cells with respect to the concurrent administration. 
On the contrary, with the resistant C13* cells both 5-FU and RTX increased their cytotoxicities when 
Figure 1. Effects of scheduled combinations of the [D-Gln4]LR peptide with cDDP, paclitaxel, 5FU and
RTX on the SQ value in A2780 and A2780/CP cell li es. (A) concurrent combina ions for 72 h.
(B) Sequential combinations, as describe in Section 4. Th bars represe t the me n of duplicate cell
counts on three separate experiments an indi ate the r sult of the i hibition of dr g ombination
divided by the sum of the inhibition of a single drug to obtain the values of SQ. Error bars, SD.
With the second pair of cell lines, 2008 and C13*, concurrent administration was additive for
cDDP, 5-FU, and paclitaxel at the lower dose, supra-additive at the higher dose of paclitaxel and
for RTX at both doses (Figure 2 and Figure 4). Sequential exposure to [D-Gln4]LR and then to the
drugs did not enhance cell killing with the cDDP-sensitive 2008 cells with respect to the concurrent
administration. On the contrary, with the resistant C13* cells both 5-FU and RTX increased their
cytotoxicities when administered after [D-Gln4]LR; in particular, RTX exhibited a synergistic efficacy at
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the lower dose. A general enhancement of cytotoxicity, with SQ values higher than unity, was obtained
with both combined treatments of IGROV-1 cells, at almost all drug doses employed (Figures 3 and 4).
Advantages of the sequential treatment according to schedule II over the concurrent treatments were
demonstrated by supra-additive or synergistic SQ values obtained with 5-FU and RTX using this
schedule, in particular at the lower concentrations tested. Interestingly, this scheduled combination
with RTX 10 nM reached a synergistic SQ value of about 1.7. On the other hand, when drug treatment
preceded exposure to the peptide (sequence III) the anti-proliferative results were antagonistic with all
drugs and cell lines tested (Figure 4). As summarized in Figure 4, the IGROV-1 and A2780 cell lines show
similar overall response profiles to the tested combinations. In fact, almost all the combinations, except
5-FU at low dose administered after [D-Gln4]LR peptide, showed synergistic activity. On the other
hand, all the combinations in which the [D-Gln4]LR peptide was administered after the drugs showed
antagonism or, in a few cases, additive activities. Regarding the tested combinations: (i) RTX-high
dose in concurrent administration with the [D-Gln4]LR peptide has a synergistic activity towards all
the tested cell lines; (ii) low-dose RTX and high-dose 5-FU administered after the [D-Gln4]LR peptide
show synergistic activity towards all cell lines, except the 2008 cells; (iii) high-dose RTX and paclitaxel
in the concurrent administration and high-dose paclitaxel administered after the [D-Gln4]LR peptide
showed synergistic activity towards all cell lines, except C13*.
Taken together these results show that scheduling may be crucial for potentiating the antitumor
effect of [D-Gln4]LR. In particular, its combination with 5-FU and RTX, i.e., drugs that target folate
cycle enzymes, but also with cDDP and paclitaxel, shows enhanced effectiveness when the drugs are
administered after the peptide.
2.2. [DGln4]LR Combination with Chemotherapy Drugs Cause Great Perturbation of Cell Cycle and
Promotes Apoptosis
Looking for a possible mechanism underlying the antiproliferative activity and correlating with
the additive or synergistic effects of the combination between [DGln4]LR with the chemotherapy drugs
cDDP, 5-FU and RTX, a perturbation of the cell distribution in the different phases of the cell cycle
was tested in cytofluorimetric experiments (DNA content analysis) on the 2008 and C13* cell lines.
The percentage of cells in the different phases of the cell cycle is reported in Figures 5 and 6, Table S2
and Figures S1–S3.
Figure 5 and Table S2 report the results obtained with 2008 and C13* cell lines treated with 5 µM
peptide and two pairs of 5-FU concentrations (5–10 µM and 10–20 µM), in sensitive and resistant cells,
respectively. After 72 h, untreated cells of both lines showed a normal diploid distribution presenting
fast proliferation characteristics. 5-FU, both alone and in combination, had a very scant effect in
perturbing the distribution of the C13*-resistant cells in the different phases of cell cycle, even if a
synergistic but modest accumulation of cells in sub-G1 phase was observed with 20 µM 5-FU, a finding
indicative of apoptotic cell death (hypodiploid cells).
On the contrary, 2008 cells were more sensitive to both concentrations of 5-FU (5–10 µM) showing
a reduction of cell accumulation in the G0/G1 phase, coupled with an increase of cell accumulation in
both S and sub-G1 phases. The increase of sub-G1 phases (apoptotic cells) was almost doubled by
combination with the peptide, reaching approximately 20% of synergistic cell killing (SQ = 1.38-1.33).
The other two chemotherapy drugs, cDDP and RTX caused a great decrease of sensitive cell
accumulation in the G0/G1 phase that paralleled with a remarkable increase of percentage of the sub-G1
phase cell population (apoptotic cells), The combination of the peptide with each chemotherapy drug
produced a synergistic accumulation of hypodiploid 2008 cells in comparison to single drug treatment
(SQ = 1.1-1.2). This effect was also accompanied by a decrease of cell accumulation in all phases of cell
cycle (Figure 6, Figures S1 and S2, Table S3). Notably, treatment with each drug alone deranged the
cell-cycle phase distribution even in the resistant C13* cells, in which the percentage of the sub-G1
phase population was synergistically increased by combining the peptide with cDDP (SQ = 1.7) and
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with RTX (SQ = 1.13). RTX alone was also very effective as an apoptosis-inducing agent, particularly in
sensitive cells.
Interestingly, an additive and a synergistic accumulation of cell population in the sub-G1 phase
was also observed in the sensitive and resistant cells, respectively, already after 48 hr treatment with
combinations of the peptide with either cDDP or RTX (Table S3 and Figure S3).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 22 
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2.3. Liposome Characterization
Next, we move on, and pass from the SAINT-PhD delivery system to the engineered PEGylated
liposomes, which represent an advancement towards a more drug-like delivery system. The PEGylated
liposomes strategy is deemed necessary to implement further in vivo studies of the [D-Gln4]LR peptide
in combination with standard drugs.
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Liposomes showed a size of about 200 nm with a good dimensional homogeneity, as shown by
the low polydispersity index (PDI) value (Table 1). Moreover, the PDI did not show any significant
alteration after drug addition, indicating that neither the homogeneity nor the stability of the liposomes
were affected by the inclusion of the drug. The same occurred with the surface charge.
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Table 1. Physicochemical characterization of the optimized unloaded and [D-Gln4]LR-loaded
liposomes. Each value represents the mean ± SD; PDI: polydispersity index; DL: drug loading;
EE: encapsulation efficiency.
Sample Z-Average (nm) PDI Z-Potential (mV) DL (µg/mg) EE (%)
DOPE:CHEMS:DSPE_PEG
(PpHL) 198 ± 30 0.279 ± 0.077 −14.54 ± 2.41 - -
[D-Gln4]LR_ DOPE:CHEMS:DSPE_PEG
([D-Gln4]LR-PpHL)
209 ± 19 0.289 ± 0.072 −14.28 ± 2.19 21.03 ± 1.66 42 ± 3
The peptide was efficiently encapsulated in the liposomes. The drug loading (DL) was
21.03 ± 1.66 µg peptide/mg of lipid and the encapsulation efficiency approximately 40%. Consistently
with the two-fold drug/lipid ratio used in the preparation, this formulation exhibited a DL twice that of
the already reported homologue formulation [26]. The obtained loaded liposomes efficiently retained
the peptide: after an 8 h incubation, only 30% of the initially encapsulated peptide was released and no
further escape was observed in the next 16 h (Figure 7).
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2.4. Cytotoxicity of Peptide-Loaded Liposomes
The antiproliferative activity of the peptide encapsulated in these optimized liposomes (PpHL)
was tested by the MTT assay on three OC cell lines, the cDDP-resistant C13* cells and their sensitive
counterparts, the 2008, and the IGROV-1 cell lines, the latter sensitive to cDDP too.
In the first experiment, the cells were exposed to increasing concentrations of the peptide-loaded
liposomes ([D-Gln4]LR-PpHL) according to the optimised protocol reported, using the unloaded
carriers as a control. Moreover, the free [D-Gln4]LR peptide at the equivalent concentration was used
for comparison. The elaborated results are reported in Figure 8. The unloaded liposomes (PpHL) were
not toxic towards all cell lines since cell viabilities higher than 85% were observed for all the liposome
concentrations and cells considered (Figure 8A).
Concerning the effect of [D-Gln4]LR-PpHL, a marked difference in cytotoxicity between loaded
and unloaded carriers was observed, particularly with the cDDP-sensitive 2008 cell line. Indeed,
at the higher liposome concentration, 0.25 mg/mL, a 50% viability was obtained with these cells,
while a slightly higher survival, 63%, was exhibited by the cDDP-resistant C13* cells. On the other
hand, IGROV-1 cells, despite their cDDP-sensitivity, proved quite resistant to the peptide-loaded
liposomes, exhibiting cell viabilities about 80% with all the amounts of liposomes employed. It should
be noticed that IGROV1 cells are known to exhibit a different behaviour to drug treatment. Despite
being sensitive to cisplatin in vitro, they are resistant to Asta Z, and present an intermediate drug
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response to adriamycin. Finally, concerning the effect of drug loading, its doubling caused only a
moderate increase in cytotoxicity on the C13* cells, with a 63% survival vs a 70% survival measured
with the original preparation [26], a finding likely due to the saturation of the intracellular target
enzyme, hTS.
The importance of these liposomes as vehicles for the peptide internalization into cells was
confirmed by the inability of the free [D-Gln4]LR peptide to interfere with the growth of all three cell
lines [26].
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2.5. Sequence-Dependent Synergistic Antiproliferative Effect of Peptide-Loaded Liposomes in Combination with
RTX or cDDP
The peptide-loaded liposomes [D-Gln4]LR-PpHL at a concentration of 0.125 mg/mL, corresponding
to 2.12 µM overall extracellular peptide concentration, was combined with RTX and cDDP at different
concentrations, according to the cell line sensitivities to these drugs, 10 nM RTX and 5 µM cDDP for
C13*, 10 nM RTX and 2.5 µM cDDP for IGROV-1 and 2008 cells, respectively. Peptide-loaded liposomes
combined with the two anticancer drugs showed greater efficacy against both cDDP-sensitive and
-resistant cell lines when administered concurrently or sequentially (liposome, L+drug, D) (sequences I
and II, respectively), while the reversed schedule (D+L, sequence III) produced an antagonistic effect;
the combination sequences leading to the synergistic antiproliferative effect are the same observed
with the SAINT-PhD delivery system (Figures 1–4). Noteworthy, sequences I and II synergistically
killed even IGROV-1 cells, i.e., the least responsive to the peptide-loaded liposomes alone (Figure 8A).
The SQ values obtained are shown in Figure 8B.
3. Discussion
The [D-Gln4]LR peptide and its lead, LR, have exhibited cancer cell-growth inhibitory activity by
mainly reducing the abundance of the active form of hTS, and, unlike 5-FU and PMX, without inducing
overexpression of the enzyme [19,21], but even by down-modulating the expression of other folate
pathway genes, DHFR and AICAR transformylase (ATIC) [22]. Cells that acquire resistance to classical
TS inhibitors because of an enhanced TS expression exhibit general cross-resistance with platinum-based
drugs [3] and display cross-resistance to antifolates such as RTX [27,28].
Antifolates targeting hTS are not well known in OC therapy. All those inhibitors bind at the
protein active site and this cause the loss of the translational control and TS levels regulations [29].
Our hypothesis was that if TS levels are reduced, drug resistance mechanisms will be limited or
prevented. So, we propose a change of paradigm in TS inhibition based on new drugs that, unlike
the well-known, traditional TS inhibitors (RTX, PMX, 5FU), bind at the protein interface. [22,30–32].
These compounds can be combined with platinum drugs, RTX, PMX or 5FU to keep TS levels low and
contrast drug resistance development.
Owing to the intricate biochemical interconnections and the difference in biological pathway
modulation between the peptides and the classical drugs that, in order to explore strategies to
overcome tumour drug resistance and achieve greater therapeutic gains, the present in vitro study has
investigated the effects of combining the novel TS inhibitor peptides with cDDP [1], as well as some
classical antifolate agents. To provide a mechanistic interpretation of the results of our combination
experiments, we first start from known individual drug effects as well as some drug-combination
literature reports.
Combination of cDDP with classical folate cycle inhibitors, such as 5-FU, has been explored in
experimental and clinical studies and has exhibited a pronounced activity against various types of
human tumours, including chemo-resistant ovarian carcinoma [33,34]. However, the response and
toxicity varied considerably according to the schedule and dose used [35,36]. The explanation of
the synergistic response attained with 5-FU plus cDDP likely involves more than one mechanism.
On one hand, it was correlated to increased TS inhibition related to higher levels of FdUMP, the active
5-FU metabolite. This, in turn, was associated with an increase in the intracellular reduced folate levels
in the tumour cells by inhibition of the transport of L-methionine by cDDP, a well-known biochemical
mechanism by which cDDP potentiates the cytotoxicity of 5-FU, [33,37]. However, a greater degree of
fragmentation of both nascent and parent DNA was indicated as another possible mechanism of the
5-FU/cDDP synergism [38]. Finally, the better objective response to this drug combination exhibited by
5-FU-resistant patients has been explained by showing that TS inhibition by treatment with platinum
drugs and 5-FU also occurs at the transcriptional level [39]. Overall, these explanations establish a
causal relationship between hTS inhibition and a decreased efficiency of the mechanisms of repair and
substitution of damaged DNA. This might apply to our case as well: the peptide delivered by the
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liposomes, before (sequence II) or concurrent (sequence I) with cDDP, causing the folate cycle enzyme
inhibition, may hamper the repair and substitution of the DNA damaged by cDDP. Additional support
to this mechanistic hypothesis comes from the previously reported evidence that treatment of OC cells
with the TS inhibiting peptide [D-Gln4]LR induces deregulation of such folate-related proteins as TS,
DHFR and SHMT1 [21]. In particular, the idea that cDDP and the peptide may act synergistically on
the folate pathway is reasonable since TS and DHFR operate in the same metabolic cycle [40–42].
Other nodal proteins of the folate pathway were found to be affected by the LR and [D-Gln4]LR
peptides. Among these, ATIC, is an enzyme involved in purine biosynthesis, and NME2, also known
as nucleoside diphosphate kinase B, plays a major role in the synthesis of nucleoside triphosphates
other than ATP [22]. Because both ATIC and NME2 are down-regulated following treatment with our
peptidic inhibitors and are modulated at the gene level by c-Myc [43], a role of this proto-oncogene in
the mechanism of action of the two peptides seems likely. Furthermore, the involvement of c-Myc in
the mechanism of the observed synergistic effect of the peptides with cDDP and 5-FU is suggested by
the known important role played by the downregulation of c-Myc in the cell response to cisplatin and
to 5-FU [43–45].
The observed synergy of the peptide with RTX might be related to several different effects: RTX
and/or its polyglutamated derivatives reduces the purine biosynthesis as suggested by the increase in
the intracellular levels of phosphoribosylpyrophosphate (PRPP) following a 24 h exposure of colon
carcinoma cells to RTX [46]. Because RTX is also a moderate direct inhibitor of DHFR, the observed
peptide/RTX synergy could result from inhibition of this enzyme and the consequent increase of PRPP
levels in the cell via inhibition of purinic biosynthesis [45], thereby potentiating the cellular inhibitory
effects of the peptide.
In addition, the synergistic effect of combining the peptides with cDDP or the other drugs may
derive from mis-incorporated genomic uracil, resulting from TS inhibition, which induces DNA
damage and early cell-cycle arrest as a result of BER activity, and is a critical determinant of sensitivity
to antifolate-based TS inhibition [46].
Our findings on the dependence of the effects of the combination of peptides and RTX on the
administration schedule correlate with previous reports where synergistic effects, were obtained by
a sequential exposure to the DHFR inhibitor methotrexate (MTX) followed by RTX [47]. Actually,
the interaction between different antifolates or between antifolates and a Pt drug quite generally
follows a preferential treatment schedule. In most cases, simultaneous and continuous administration
of RTX and cisplatin, or the sequential administration of RTX followed by cisplatin, produce the
highest cytotoxicity, while the reversed sequential administration produces antagonistic effects and
thus resulting inappropriate [42].
In our case, the observed sequence-dependent synergy might be accounted for in connection
with the finding that HSP90 and TRAP1, that are critical regulators of survival of tumour cells,
are among the proteins down-regulated by the peptides. TRAP1 has been described as a mitochondrial
chaperone of HSP90AA1. Effective cytoprotection may require TRAP-1 phosphorylation by the
mitochondrial-localized kinase, PINK1, which associates with TRAP-1 in vivo. The high expression of
TRAP-1 in cancer has been implicated in the inhibition of mitochondrial apoptosis, suppression of
ROS production and acquisition of resistance to standard chemotherapeutics [48]. On the opposite
hand, decreased TRAP1 expression leads to the accumulation of ubiquitinated/misfolded proteins and
proteotoxic stress, a condition that makes cells more sensitive to apoptotic insults, including those
caused by treatment with such drugs as cDDP [1]. HSP90 is a ubiquitously expressed molecular
chaperone that is involved in the posttranslational folding and stability of multiple mutated, chimeric
and over-expressed signalling proteins that promote the growth and/or survival of cancer cells [49].
Previous studies have shown that HSP90 is highly expressed in OC, and a sub-member, HSP90AA1,
has been shown to be required for the survival and proliferation of human OC SKOV3 cells. High levels
of HSP90AA1 can increase chemo-resistance to cisplatin of SKOV3 cells [50]. Moreover, the concomitant
overexpression of ATIC and TRAP1 has been associated to chemoresistance to both cisplatin and
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5-FU [51,52]. Therefore, inhibition of HSP90 could potentially act as a promising adjuvant to
chemotherapies to overcome drug resistance. Inhibition of these two chaperones, HSP90AA1 and
TRAP1 has been already reported following treatment with the antifolate drug MTX and yielded a
synergistic effect by interfering with the synthesis of purines [53]. In this light, disabling of HSP90
cancer networks in their multiple subcellular compartments, mitochondrial and cytosolic, by our
peptidic inhibitors, may cause irreversible collapse of mitochondria, degradation of HSP90 client
proteins in the cytosol, and tumour cell killing by apoptosis and/or autophagy, thus favoring the action
of both cDDP and RTX. Also, because RTX induces mitochondrial mediated apoptosis in SGC7901
human cancer cells by disrupting the PI3K/AKT/Hsp-90 cascade and mitochondrial integrity [54–56],
a peptide-induced HSP90 disabling may explain the higher efficacy of a sequential treatment schedule.
The combination synergy of the peptide with paclitaxel, that like the other mentioned
chemotherapeutic drugs, is frequently used in OC therapy, is justified by several experiments that
report, already at the clinical level, on the positive effects of the combination of this microtubule
stabilizer with folate-cycle inhibitors and/or platinum drugs [57–59].
4. Materials and Methods
4.1. Materials
Raltitrexed (RTX) and paclitaxel were purchased from Selleckchem (Houston, TX, USA) and were
dissolved in DMSO immediately before addition to the cell cultures. Cisplatin (cDDP) was obtained
from Santa Cruz Biotechnology. All other chemicals were purchased from Sigma–Aldrich S.r.L. (Milan,
Italy), except otherwise indicated.
Reagents for liposome formulation: cholesteryl hemisuccinate (CHEMS) purchased from
Sigma–Aldrich (St. Louis, MO, USA); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and
[N-(Cabonyl-methoxypolyethyleneglycol-2000)]-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
sodium salt (DSPE_PEG) purchased from Lipoid (Ludwigshafen, Germany). The active peptide
[D-Gln4]LR and the internal standard (IS) for quantitative analysis, LR-Ala7, were synthesized as
previously described [21,22]. All the other reagents were of analytical grade.
4.2. Cell Lines
The five human cancer cell lines of ovarian origin, IGROV-1, A2780, A2780/CP, 2008 and C13*,
were grown as monolayers in RPMI 1640 medium containing 10% heat-inactivated foetal bovine
serum and 50 µg/mL gentamycin sulphate. The 2008 cell line was established from a patient with
serous cystadenocarcinoma of the ovary, and their cisplatin (cDDP)-resistant variant C13* cell line,
was developed by monthly exposure to cDDP, followed by chronic exposure to stepwise increases
in cDDP concentration [60,61]. The human ovarian carcinoma A2780/CP cells are about 10 fold
resistant to cDDP and derived from the parent A2780 cell line [62]. The IGROV-1 cell line, originating
from an ovarian carcinoma of a 47 years old woman, was established in monolayer tissue culture.
The IGROV-1 cell line exhibits an epithelial character, highly tumorigenic properties and a low doubling
time. In addition, there are consistent cytogenetic markers in which oncogenic rearrangements
can occur. IGROV-1 is therefore proposed as a model for experimental studies of human ovarian
adenocarcinoma, including molecular and cell biology, preclinical pharmacology and experimental
therapeutics [63]. The cells were incubated at 37 ◦C under 5% CO2 for at least 24 h before treatment
with the peptides. All cell media and serum were purchased from Lonza (Lonza Group Ltd., Basel,
Switzerland). Cultures were equilibrated with humidified 5% CO2 in air at 37 ◦C. All studies were
performed in Mycoplasma negative cells, as routinely determined with the MycoAlert Mycoplasma
detection kit (Lonza Group Ltd., Basel, Switzerland).
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4.3. Cell Transfection with [D-Gln4]LR Peptide by Means of the Delivery System SAINT-PhD
Treatment with peptide was performed according to the standard transfection protocol of the
SAINT-PhD delivery system (Synvolux Therapeutics, Groningen, the Netherland). Complexes of
peptide (µg) with SAINT-PhD (µL) were prepared at a ratio of 8 µg/20 µL (which corresponds to a
concentration of 5 µM final). For each protein sample, complexes were prepared as follows: for the
treatment of a 24-well, an appropriate amount of the peptide was diluted in HBS, then SAINT-PhD
was pipetted into the solution without vortexing. The mixture was incubated for 5 min at room
temperature, then filled with serum-free medium. The culture medium was aspirated from the cells,
the SAINT-PhD/peptide complex was added to the wells and incubated 4 h (37 ◦C; 5% CO2). After this
time, complete RPMI was added to reach the appropriate volume.
4.4. Liposome Characterization
DOPE:CHEMS:DSPE_PEG (PpHL) liposomes were prepared using the Reverse Phase Evaporation
technique followed by homogenization using Ultraturrax (Ika-euroturrax T 25 basic, IkaLabortechnik,
Staufen, Germany). Briefly, phospholipid solutions in chloroform at fixed concentration,
DOPE:CHEMS:DSPE (22.8: 15.2: 2 mM) for nPpHL liposomes and DOPE:CHEMS:DSPE_PEG (22.8:
15.2: 2 mM) for PpHL liposomes, were employed and an amount of 4 mg of [D-Gln4]LR was loaded
in the liposomes obtaining a final suspension of 15 mg/mL in HBS (Hepes Buffer Saline with 20 mM
Hepes and 135 mM NaCl) [29]. Size, size homogeneity and surface charge of the liposomes diluted in
water (1:5 v:v) were measured by Zetasizer Nano ZS analyser system (Zetasizer version 6.12; Malvern
Instruments, Worcs, UK), equipped with a 4 mW He–Ne laser (633 nm) and a DTS software (Version 5.0).
Measurements were performed in triplicate and each measurement was averaged over at least 12 runs.
Drug loading (DL), encapsulation efficiency (EE) and drug release were analysed by liquid
chromatography (Agilent 1200 Series LC system; Agilent, Technologies, Milan, Italy) coupled with
triple-quadrupole mass spectrometry (LC-MS/MS) (Agilent 6410 triple quadrupole-mass spectrometer,
Agilent technologies, Milan, Italy), as described previously [26].
4.5. Cytotoxicity of Liposome-Drug Combinations by MTT Assay
The cytotoxicity assay was performed by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide; Sigma, Milan, Italy) assay (MTT assay) [64]. Briefly, C13*, 2008 and IGROV-1 cell lines were
seeded at a density of 30,000 cells/well in 24-well plate in complete RPMI-1640 medium for at least
24 h. Immediately prior to the cell treatment, the culture medium was aspirated from each well and
replaced with 500 µL of complete medium, containing either the unloaded or the [D-Gln4]LR-loaded
liposomes at concentrations of 0.05, 0.075, 0.125 and 0.250 mg/mL; moreover, cells were treated,
for comparison, with equivalent amounts of naked peptide. Cells were then incubated in complete
medium suspension in 5% CO2 incubator at 37 ◦C for 15 h. Then, they were washed with PBS, added
with 500 µL of complete RPMI-1640 medium and incubated for additional 48 h. After incubation,
a final concentration of 0.5 mg/mL MTT was added to the medium and then incubated at 37 ◦C for 1 h.
The medium was removed and the dark blue formazan crystals dissolved in DMSO were determined
spectrophotometrically at 535 nm by the multi-plate reader Genios Pro (Tecan, Austria) with Magellan
6 software, and the results are expressed as percentage of cell growth with respect to the control
(untreated cells).
4.6. Synergy Analysis
The nature of the combination between [D-Gln4]LR-PEG liposomes and drugs (namely cDDP or
RTX), combined at a fixed ratio either simultaneously or sequentially, was quantified by synergism
quotient (SQ) [65,66]. SQ was defined as the net growth inhibitory effect of the analogue combination
divided by the sum of the net individual analogue effects on growth inhibition. A quotient of > 1
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indicates a synergistic effect, between 0.9 and 1.1 indicates an additive effect, while a quotient of < 1
indicates an antagonistic effect.
C13*, 2008 and IGROV-1 cell lines were exposed to the combinations using 3 different modalities.
Simultaneous drug-exposure (sequence I): cDDP or RTX were given simultaneously with liposomes
for 3 days; liposomes before (sequence II): [D-Gln4]LR loaded liposomes was given 24 h before cDDP
or RTX; drugs before: the drug (cDDP or RTX) was given 24 h before liposomes (sequence III).
All the incubation experiments were carried out according to the optimized protocol in which
cells were exposed to liposome treatments for 15 h after the medium had been replaced with fresh one.
Growth inhibition was assayed by MTT assay and the cytotoxicity of each combination was compared
with the cytotoxicities of the drugs alone. Each experiment was performed at least 3 times.
The heatmap and clustering have been realized with the open source software R and
Bioconductor repository, using ggplot2 and Heatplus packages (https://cran.r-project.org/ [67];
https://www.bioconductor.org/ [68]). For the clustering (Euclidean distance, complete linkage
clustering), in order to highlight the distance between antagonism, addition and synergy values, the
synergism quotient values were elaborated as follow: for synergism quotient values < 0.9, a value of
10 was subtracted; for synergism quotient values ≥ 1.1, a value of 10 was added.
4.7. Flow Cytometric Analysis of Cell Cycle
Quantitative measurements of the cell cycle phase distribution were performed by flow
cytometry [69]. Cells were suspended in 0.5 mL of hypotonic fluorochrome solution (25 µg/mL
PI, 0.1% sodium citrate, 0.1% Triton X-100). The samples were kept at 4 ◦C in the dark for at least
30 min, dispersed by repeated pipetting before flow cytometry analysis in a FACSCoulter Attune®
NxT Acoustic Focusing Cytometer (Invitrogen, Milan, Italy) equipped with a single 488 nm argon
laser. The percentage of nuclei in the different phases of the cell cycle (G0/G1, S and G2/M) was
calculated with a DNA cell cycle analysis software (Attune® NxT Software version 1.0). A minimum
of 1 × 104 cells/sample were analysed for each sample.
4.8. Statistical Analysis
A statistical analysis was performed using the one-way analysis of variance (ANOVA). The data
are represented as means ± SD. A difference was considered statistically significant at * p < 0.05,
** p < 0.01 or *** p < 0.005.
5. Conclusions
This work has demonstrated that the TS allosteric inhibitor, the [D-Gln4]LR peptide, showed a
schedule-dependent synergistic antiproliferative effect against OC cells in combination with cDDP,
RTX, 5-FU and paclitaxel. More precisely, simultaneous exposure as well as 24 h pre-treatment with the
peptide, produced a synergistic cell killing, while a reversed schedule that consists in pre-treating with
the non-peptidic drugs was always antagonistic. Furthermore, for the first time, we have provided
evidence that this peptide can overcome resistance to cDDP, as its combination with this alkylating agent
was synergistic also against the cDDP-resistant cell lines. Also, we have demonstrated a synergistic
antiproliferative effect of the peptide in combination with 5-FU, or with RTX even against the C13*
and A2780/CP cell lines that had been selected for their resistance to cDDP and cross-resistance to
5-FU and RTX, and feature amplified expression of the folate cycle enzymes [43]. Most of these effects
paralleled with great alteration of cell cycle and additive or synergistic accumulation of apoptotic
cells. Additionally, the present study indicates how liposome PEGylation, without changing the
behaviour of the encapsulated drug, preserves its effectiveness and its therapeutic effect, making it
comparable with that obtained with a specific peptide delivery system. Also, delivery by PEGylated
liposomes allowed the carried peptide to be of effective formulations with other chemotherapy drugs.
Notably, our results, in line with previous published evidence, show that, for a successful, synergistic
functional combinatorial targeted therapy, careful attention must be paid to exposure, dose, schedule
Int. J. Mol. Sci. 2020, 21, 4452 17 of 21
and target engagement. Thus, the results of this drug combination investigation concerning both
in cytotoxicity and cell cycle studies imply the occurrence of complex biochemical interconnections
between the peptide and the classical drugs used in this study. Many of these interactions involve
apoptotic mechanisms accounting for the effects observed and discussed.
Overall, the results of this preclinical study suggest that the association of standard drugs with
this novel peptidic hTS inhibitor encapsulated into PEGylated pH-sensitive liposomes is a promising
strategy to impact the drug resistance problem and, combined with intracellular mechanistic analysis,
may represent a rational basis for future clinical applications in ovarian tumor patients.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/12/4452/
s1. Table S1. IC50 values (µM or nM) for selected compounds obtained after 72 h treatment of 2008, C13*, A2780,
A2780/CP, and IGROV1 human ovarian cancer cell lines. Table S2. The effect of 72h-exposure to [DGln4]LR and
5-FU alone and in combination on the cell cycle phase distribution of 2008 and C13* cell lines by cytofluorimetric
analysis. Table S3. The effect of 48h- and 72h-exposure to [DGln4]LR and cDDP alone and in combination on the
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